Journal article
Methylenetetrahydrofolate reductase (MTHFR) genetic variation and major depressive disorder prognosis: A five-year prospective cohort study of primary care attendees
CA Bousman, M Potiriadis, IP Everall, JM Gunn
American Journal of Medical Genetics Part B Neuropsychiatric Genetics | WILEY | Published : 2014
DOI: 10.1002/ajmg.b.32209
Abstract
Methylenetetrahydrofolate reductase (MTHFR) genetic variation has been associated with the diagnosis of major depressive disorder (MDD) but no study to date has examined the effect MTHFR variation has on MDD prognosis. We sought to examine the prospective effects of two common MTHFR variants (C677T and A1298C) as well as seven haplotype-tagging single nucleotide polymorphisms (htSNPs) on MDD prognosis over a 5-year (60-month) period. Participants were 147 depressed primary care attendees enrolled in the Diagnosis, Management and Outcomes of Depression in Primary Care (diamond) prospective cohort study. Prognosis of MDD was measured using three methods: (1) DSM-IV criteria, (2) Primary Care E..
View full abstractRelated Projects (5)
Grants
Awarded by National Health and Medical Research Council
Awarded by LEW Carty Chartable Fund
Funding Acknowledgements
Grant sponsor: National Health and Medical Research Council; Grant numbers: 299869, 454463, 566511, 1002908; Grant sponsor: Victorian Centre for Excellence in Depression and Related Disorders; Grant sponsor: LEW Carty Chartable Fund; Grant number: 7284.